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rapidly growing mass protruding from the vagina with intermittent vag-
inal bleeding along with profuse malodorous vaginal discharge. Her fam-
ily history was remarkable only for a sister with breast cancer in her late
30s and there was no known history of familial polyposis or Lynch syn-
drome. On the initial exam, there was a prolapsed fungated necrotic
mass measuring 9 × 5.5 cm and indistinct from her cervix. The uterus
was 12 week size and there was no adnexal mass. The biopsy of thelanta, GA 30310, USA.
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionThe roles of trophoblastic human chorionic gonadotropin (hCG) in
pregnancy have long been known. Insufﬁcient hCG expression has been
linkedwithpregnancy failure either as a spontaneous abortion or as a bio-
chemical pregnancies, aswell aswith ineffective placentationdue to inad-
equate implantation manifesting as pregnancy induced hypertension
(Cole, 2012). It has also been described that hCG β subunit is able to
crosstalkwith receptors of the cytokines in the cystine knot growth factor
superfamily (Iles et al., 2010; Iles, 2007) due to crystalline structure ho-
mologywith cystinedisulﬁdebridges (Lapthorn et al., 1994). Inparticular,
hCG is shown to block transforming growth factor β receptor mediated
apoptosis (Iles, 2007; Butler et al., 2000) and to promote vascular endo-
thelial growth factor receptor mediated angiogenesis (Herr et al., 2007;
Reisinger et al., 2007). In addition, despite the molecular origin, hCG-H,
hCGβ and hCGβ-H are all shown to behave similarly as promoters of can-
cer cell lines and their activitieswere similarly reduced by B152, antibody
to hCG (Cole, 2012). It is thought that these are mechanisms by which a
variety of non-gestational tumors that produce ectopic hCG β are able
to develop characteristic aggressive course and treatment resistance
(Iles et al., 2010). Despite the associationwith anaplastic tumor character-
ized by poor prognosis and rapid metastasis (Iles, 2007), there is no con-
sensus or trials to answer if the tumors producing ectopic hCG should be
treated differently.
Case presentation
A 64 year old African American Para 1001 woman with class II
obesity (body mass index 37), well controlled diabetes mellitus andmass showed highly pleomorphic and poorly differentiated nests of epi-
thelioid tumor cells. Her preoperative CA 125was noted to bemildly ele-
vated at 38.0 U/ml and CEAwas normal at 0.5 ng/ml. She underwent total
abdominal hysterectomy, bilateral salpingo-oophorectomy, and lymph
nodedissection. The uterusmeasured 14×9×6 cmand202 g, containing
a tumor measuring 6.5 × 3.5 × 2.5 cm (Fig. 1). The tumor was invading
more than half of the myometrium and cervix as well as pelvic lymph
nodes, making her stage IIIC1. The histology was classiﬁed as clear cell
and papillary serous adenocarcinoma as well as simple hyperplasia in
the endometrium (Fig. 2). The tumor stained positive for p53. On postop-
erative day 2, the patient was found to have dyspnea, tachypnea and
desaturation. A CT PE protocol scan revealed multiple segmental emboli
in the right lung and the patient was treated with anticoagulation.
At 6 weeks postoperatively, PET CT was obtained for evaluation of a
6 × 6 cm pelvicmass, whichwas noted to have grown rapidly at the vag-
inal cuff. Themass showed heterogeneous FDG uptake tomaximum SUV
of 12.7, and there was interval worsening of bilateral lung nodularities
with mild FDG uptake with index right upper lobe nodule 1.7 × 1.1 cm
with maximum SUV of 6.3 and index left upper lobe nodule 2.4 × 1.8 cm
with maximum SUV of 5.4. The biopsy specimen of this recurrence at
the vaginal cuff was consistent with primary uterine cancer. The clear
cell morphology of the hCG secreting stem cells present in the senior
author's trophoblast cell line (Pattillo and Gey, 1968) prompted Dr.
Pattillo to investigate whether this “clear cell” uterine cancer was pro-
ducing hCG. The patient's serum hCG level was 7431mIU/ml. Immuno-
chemistry staining of tumor for hCG was requested and it was positive
(Fig. 2). Subsequently, the tumor was submitted for further molecular
testing. Whole genome microarray of the tumor showed multiple
copy number variations (Fig. 3). These chromosomal abnormalities oc-
curred over MSH2, MSH6, TP53 genes, as well as the duplication and
overexpression of CGB genes encoding theβ subunit of hCG on chromo-
some 19. At this time, the authors held a meeting with the patient and
her family to discuss the ﬁndings and that although not standard
of care, we would like to offer EMACO (etoposide, methotrexate,
Fig. 1. Gross photograph of the uterus, tubes, ovaries. Anterior cervix replaced by the
tumor. The probe is placed into the endocervical canal.
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vant course. Risks, side effects and alternative options were discussed
and patient consented to the plan of care.
When patient presented for adjuvant chemotherapy, she was found
to have asymptomatic systemic inﬂammatory response syndrome
without a source of infection, which delayed initiation of ﬁrst cycle. In
10 days, her hCG level had nearly doubled to 14,361 mIU/ml. During
this delay, bleeding from her recurrent tumor rapidly dropped her he-
moglobin. She was given transfusions and a total 30 Gy of pelvic
radiation over 5 days to the vaginal cuff to reduce bleeding. Post
radiation, hCG was noted at 11,915 mIU/ml. She had developed
vancomycin nephrotoxicity by this time, and renally dosed EMACOFig. 2. Photomicrographs showing sheets of tumor cells with necrosis and acute inﬂammatory
occasional clearing and well deﬁned cell borders. The nuclei are high grade with occasional bi-with omission of methotrexate was started. After the 1st cycle, her
hCG was down to 2701 mIU/ml, but she was again admitted for
12 days with neutropenic fever with Klebsiella pneumoniae urinary
tract infection, which delayed her 2nd cycle. Her 2nd cycle was given
after pegﬁlgrastim, at renal dosage, again without methotrexate. Her
hCG prior to 2nd cycle was down to 42 mIU/ml. After the 2nd cycle,
she was again admitted with neutropenic fever with sepsis with
disseminated Cryptococcus laurentii and remained hospitalized for
15 days, at which time, her hCG was down to 3 mIU/ml. The patient
was hesitant about continuing EMACO secondary tomultiple complica-
tions leading to hospital admissions. Repeat PET CT was obtained
6 months from the staging surgery, showing no recurrence in pelvis,
interval resolution of FDG activity and interval decrease in sizes of
pulmonary nodules. Her hCG was 1 mIU/ml. At this time, the patient
agreed to close follow-up for recurrence surveillance but declined to
receive further chemotherapy. The patient is now 20 months from the
surgery and continues to remain free of disease as evidencedbyphysical
exam, repeat PET CT and serum hCG.
Discussion
Dedifferentiation of advanced state of some malignancies enables
acquisition of oncogenetic ectopic hCGβ expression (Cole and Butler,
2012). The more dedifferentiated the tumor becomes, the more primi-
tive cell replication becomes, and this may explain the effectiveness of
chemotherapy regimen that targets the basic cell replication, such as
EMACO (Pattillo, 1973). The hCG driven growth spurt is limited by the
expression of β subunit encoded on chromosome 19. The α subunit
on chromosome 6 is shared in all gonadotropins, and is expressed in
excess in comparison to beta subunit whose expression is limited by
transcription (Tarrade et al., 2001). EMACO chemotherapy includes
actinomycin D, a potent inhibitor of transcription and a probable
major component of EMACO affecting the transcription of hCGβ. This
processmay result in cell kill of the clear cell component of this patient'sexudates in a bloody background. Tumor cells show variable amounts of cytoplasm, with
or multi-nucleation. Positive immunohistochemistry with hCG.
Fig. 3. Overview of the whole genome microarray of the tumor showing multiple copy number variations. Blue = duplication, red = deletion, purple = allelic imbalance.
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the hCG would be eliminated.
Despite the case series demonstrating ectopic hCG expression in a
substantial proportion of tumors (Iles, 2007) and the correlation of
ectopic hCG expression and poor prognosis, there is a paucity of clinical
trials addressing treatment of hCG expressing tumors. For our patient,
EMACO proved its efﬁcacy in treating her cancer.Although the present report is an anecdotal experience, the EMACO
chemotherapy outcome suggests that prospective studies of undifferen-
tiated cancers bearing “clear cell morphology”, regardless of organ of
origin, should be examined for hCG expression and clinical trials of
EMACO regimen initiated. Such discussions and implementations are
encouraged by this case report and are being institutionally pursued.
Consequence of such a paradigm shift in cancer treatment may lead to
48 R. Lee et al. / Gynecologic Oncology Reports 12 (2015) 45–48better outcomes, based not on the organ inwhich the cancer occurs, but
rather on the genomic proteomic alterations unveiled by molecular
testing.
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